Genesis Unicorn Capital in an amended S-1 disclosed it will now offer 7.5 million units at $10 each, down from the 10 million detailed in its initial July registration.
A unit now consists of one share and three-fourths of a warrant, up from one-half a warrant as originally filed.
The new SPAC intends to target the biotechnology and pharmaceutical sectors, specifically middle market and emerging growth businesses operating with a total enterprise value from $200 million to $1 billion.
EF Hutton is sole book-runner on the offering.
The SPAC still plans to apply for a Nasdaq listing under GENQU. Read more.
